Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for GALD.SW and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for GALD.SW and 80,000+ other tickers.
See exactly how GALD.SW's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GALD.SW and 80,000+ other tickers.
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
EQT completes final sell-down in Galderma, a global dermatology company delivering science-backed solutions to healthcare professionals, consumers and patients
/PRNewswire/ -- Further to previous announcements, an affiliate of the funds known as EQT VIII ("EQT") is pleased to announce it has signed an agreement to
L'ORÉAL GROUPE TO REINFORCE ITS STRATEGIC INVESTMENT IN GALDERMA WITH AN ADDITIONAL 10% BRINGING ITS TOTAL PARTICIPATION TO 20% Clichy, December 8th, 2025 - L'Oréal today announces the acquisition of an additional 10% in Galderma Group AG from a consortium led by EQT, which includes Sunshine SwissCo GmbH (SSCO), Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte.
LE GROUPE L'OREAL ANNONCE LE RENFORCEMENT DE SON INVESTISSEMENT STRATEGIQUE DANS GALDERMA EN PRENANT 10% SUPPLEMENTAIRES ET DETENIR AINSI 20% DU CAPITAL Clichy, le 8 décembre 2025 - L'Oréal annonce aujourd'hui l'acquisition de 10 % supplémentaires de Galderma Group AG auprès d'un consortium mené par EQT comprenant Sunshine SwissCo GmbH (SSCO), Abu Dhabi Investment Authority (ADIA), et Auba Investment Pte.